# Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Source: https://onco.cc/trials/nct07501169/  
OnCo record `nct07501169` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab tirumotecan and anlotinib in lung cancer, run by Sichuan University, not yet recruiting.

## Summary

Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) is a phase 2, interventional study registered as NCT07501169 by Sichuan University, with a registry enrolment figure of 33 participants, started 2026-04-01 and due to reach its primary completion in 2027-08-31. Interventions recorded: Sacituzumab Tirumotecan and Anlotinib. Conditions listed: Extensive-stage Small Cell Lung Cancer (ES-SCLC). Primary outcome: Objective Response Rate (ORR). Lung eligibility wording from the registry: "Histologically or cytologically confirmed small cell lung cancer (SCLC) based on pathology and immunohistochemistry/immunophenotyping results; disease staged as extensive-stage SCLC (ES-SCLC) according to the Veterans Administration Lung Study Group (VALG) staging system". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: STAR-01
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07501169
- Phase: 2
- Setting: Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Prospective, Single-Arm, Phase II Study (STAR-01)
- Sponsor: Sichuan University
- Enrolled: 33

## Sources

- ClinicalTrials.gov NCT07501169: https://clinicaltrials.gov/study/NCT07501169

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/), [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07501169.json